Clinical trial
A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma
Name
M13-494
Description
A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone.
Trial arms
Trial start
2018-10-22
Estimated PCD
2026-02-25
Trial end
2026-02-25
Status
Active (not recruiting)
Phase
Early phase I
Treatment
Pomalidomide
capsule, oral
Arms:
Arm 2 PomDex
Other names:
Pomalyst
Dexamethasone
oral, locally available form
Arms:
Arm 1 VenDex, Arm 2 PomDex
Venetoclax
tablet; oral
Arms:
Arm 1 VenDex
Other names:
ABT-199, GDC-0199
Size
265
Primary endpoint
Progression-Free Survival (PFS)
Up to approximately 43 months from first randomization
Eligibility criteria
Inclusion Criteria:
* Documented diagnosis of multiple myeloma (MM) based on standard International Myeloma Working Group (IMWG) criteria.
* Measurable disease at screening as defined per protocol.
* Has received at least 2 prior lines of therapy as described in the protocol.
* Has had documented disease progression on or within 60 days after completion of the last therapy.
* Has received at least 2 consecutive cycles of lenalidomide and be relapsed/refractory to lenalidomide, as defined per protocol.
* Has received at least 2 consecutive cycles of a proteasome inhibitor (PI).
* Has t(11;14)-positive status determined by an analytically validated fluorescent in situ hybridization (FISH) assay per centralized laboratory testing.
* An Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
* Laboratory values (liver, kidney and hematology laboratory values) that meet criteria as described per protocol.
Exclusion Criteria:
* History of treatment with venetoclax or another B-Cell Lymphoma (BCL)-2 inhibitor or pomalidomide.
* History of other active malignancies, including myelodysplastic syndromes (MDS), within the past 3 years (exceptions described in the protocol).
* Evidence of ongoing graft-versus-host disease (GvHD) if prior stem cell transplant (SCT).
* Prior treatment with any of the following: allogeneic or syngeneic SCT within 16 weeks prior to randomization; or autologous SCT within 12 weeks prior to randomization.
* Known central nervous system involvement of MM.
* Concurrent conditions as listed in the protocol.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 265, 'type': 'ACTUAL'}}
Updated at
2024-02-09
1 organization
3 products
1 abstract
1 indication
Product
DexamethasoneIndication
Multiple MyelomaProduct
VenetoclaxOrganization
AbbVieProduct
PomalidomideAbstract
Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis.Org: Alexandra Hospital - University of Athens, Medical School, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Würzburg University Hospital, Singapore General Hospital and SingHealth Duke NUS Blood Cancer Center, Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center,